Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers.
COVID-19
SARS-CoV-2
T cells
antibodies
vaccine
Journal
Immunology
ISSN: 1365-2567
Titre abrégé: Immunology
Pays: England
ID NLM: 0374672
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
05
10
2021
received:
09
08
2021
accepted:
03
11
2021
pubmed:
15
11
2021
medline:
15
1
2022
entrez:
14
11
2021
Statut:
ppublish
Résumé
Accurate assessment of SARS-CoV-2 immunity is critical in evaluating vaccine efficacy and devising public health policies. Whilst the exact nature of effective immunity remains incompletely defined, SARS-CoV-2-specific T-cell responses are a critical feature that will likely form a key correlate of protection against COVID-19. Here, we developed and optimized a high-throughput whole blood-based assay to determine the T-cell response associated with prior SARS-CoV-2 infection and/or vaccination amongst 231 healthy donors and 68 cancer patients. Following overnight in vitro stimulation with SARS-CoV-2-specific peptides, blood plasma samples were analysed for T
Identifiants
pubmed: 34775604
doi: 10.1111/imm.13433
pmc: PMC8653009
doi:
Substances chimiques
COVID-19 Vaccines
0
IFNG protein, human
0
Interferon-gamma
82115-62-6
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
250-259Subventions
Organisme : Medical Research Council
ID : MC_PC_20060
Pays : United Kingdom
Organisme : Medical Research Council
ID : UK Coronavirus Immunology Consortium
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 209213/Z/17/Z
Pays : United Kingdom
Organisme : HCRW_
ID : HCRW_HF-19-1595
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S00081X/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C16731/A21200
Pays : United Kingdom
Informations de copyright
© 2021 The Authors. Immunology published by John Wiley & Sons Ltd.
Références
Clin Infect Dis. 2021 Nov 2;73(9):e3130-e3132
pubmed: 33035306
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Immunology. 2022 Feb;165(2):250-259
pubmed: 34775604
Clin Microbiol Infect. 2021 Feb;27(2):286.e7-286.e13
pubmed: 33045370
PLoS One. 2021 Jan 26;16(1):e0245382
pubmed: 33497420
Ann Clin Biochem. 2021 Mar;58(2):123-131
pubmed: 33269949
Clin Infect Dis. 2022 May 06;:
pubmed: 35521791
Eur Respir J. 2022 Jan 13;59(1):
pubmed: 34140294
J Clin Invest. 2020 Oct 1;130(10):5235-5244
pubmed: 32634129
Nat Immunol. 2016 Feb;17(2):204-13
pubmed: 26726811
Sci Rep. 2020 Nov 30;10(1):20834
pubmed: 33257703
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Sci Transl Med. 2021 Apr 21;13(590):
pubmed: 33723016
Lancet Reg Health Eur. 2021 May;4:100098
pubmed: 33969335
Clin Med Insights Oncol. 2014 May 01;8:57-64
pubmed: 24855405
Science. 2020 Jul 17;369(6501):256-257
pubmed: 32675364
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
Curr Protoc Microbiol. 2020 Jun;57(1):e100
pubmed: 32302069
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33261718
Nat Immunol. 2021 May;22(5):620-626
pubmed: 33674800
BMJ. 2020 Nov 11;371:m4262
pubmed: 33177070
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
J Exp Med. 2021 May 3;218(5):
pubmed: 33646265
Eur J Immunol. 2013 Nov;43(11):2797-809
pubmed: 24258910
Eur Respir J. 2011 Jan;37(1):88-99
pubmed: 21030451
Nat Rev Immunol. 2020 Aug;20(8):457-458
pubmed: 32636479
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695